About This Event
MIRA Pharmaceuticals (Nasdaq: MIRA) visits the Nasdaq MarketSite in Times Square following the company’s August 3, 2023 IPO. The company is an early-stage life sciences company focused on the development and commercialization of MIRA1a, a Novel synthetic THC Analog. MIRA1a is being developed to treat anxiety, cognitive decline, and chronic pain in the elderly, without the impurities or the negative side effects associated with THC.
In honor of the occasion, Erez Aminov, CEO of MIRA Pharmaceuticals, rings the Opening Bell.